MediciNova, Inc. has successfully enrolled the target number of participants in its Phase 2b/3 clinical trial of MN-166 for the treatment of ALS. Dr. Yuichi Iwaki, the company’s President and CEO, expressed gratitude to patients, families, caregivers, investigators, and study teams for their dedication. MN-166 is a small molecule compound in late-stage development for ALS, MS, and other conditions. MediciNova is a biopharmaceutical company with a strong pipeline of therapies for inflammatory, fibrotic, and neurodegenerative diseases. The company has 11 programs in clinical development and a track record of securing government-funded clinical trials.

Read more at GlobeNewswire: MediciNova Achieves Enrollment in COMBAT-ALS Clinical